YU210773A - Process for obtaining imidazoquinazolin-2-one derivatives - Google Patents

Process for obtaining imidazoquinazolin-2-one derivatives

Info

Publication number
YU210773A
YU210773A YU02107/73A YU210773A YU210773A YU 210773 A YU210773 A YU 210773A YU 02107/73 A YU02107/73 A YU 02107/73A YU 210773 A YU210773 A YU 210773A YU 210773 A YU210773 A YU 210773A
Authority
YU
Yugoslavia
Prior art keywords
imidazoquinazolin
derivatives
obtaining
obtaining imidazoquinazolin
Prior art date
Application number
YU02107/73A
Other languages
English (en)
Inventor
W N Beverung
R A Partyka
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of YU210773A publication Critical patent/YU210773A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
YU02107/73A 1972-02-04 1973-08-03 Process for obtaining imidazoquinazolin-2-one derivatives YU210773A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22372372A 1972-02-04 1972-02-04
US29145072A 1972-09-22 1972-09-22

Publications (1)

Publication Number Publication Date
YU210773A true YU210773A (en) 1983-02-28

Family

ID=26918072

Family Applications (2)

Application Number Title Priority Date Filing Date
YU02107/73A YU210773A (en) 1972-02-04 1973-08-03 Process for obtaining imidazoquinazolin-2-one derivatives
YU01510/81A YU151081A (en) 1972-02-04 1981-06-15 Process for producing precursors of a new hypotensive and agent, respectively, for inhibiting the aggregation of blood platelets

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU01510/81A YU151081A (en) 1972-02-04 1981-06-15 Process for producing precursors of a new hypotensive and agent, respectively, for inhibiting the aggregation of blood platelets

Country Status (9)

Country Link
JP (1) JPS5623994B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU475978B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE794964A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1009652A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE2305575A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2173988B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1418822A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK15581A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (2) YU210773A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31617E (en) * 1972-02-04 1984-06-26 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (nl) * 1977-07-25 1979-01-29 Hoffmann La Roche Tricyclische verbindingen.
US4146718A (en) * 1978-04-10 1979-03-27 Bristol-Myers Company Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides
CA1131631A (en) * 1979-06-20 1982-09-14 Madhukar S. Chodnekar Quinazoline derivatives and pharmaceutical preparations
ZW16481A1 (en) * 1980-08-15 1982-03-10 Hoffmann La Roche Novel imidazoquinazoline derivatives
JPS6028979A (ja) * 1983-07-14 1985-02-14 Dai Ichi Seiyaku Co Ltd イミダゾキナゾリン類化合物
CZ281628B6 (cs) * 1991-07-29 1996-11-13 Warner-Lambert Company Deriváty chinazolinu a farmaceutické přípravky na jejich bázi
AU705229B2 (en) 1994-08-09 1999-05-20 Eisai R&D Management Co., Ltd. Fused pyridazine compound
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN117062819A (zh) * 2021-03-23 2023-11-14 北京生命科学研究所 多环化合物及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE760013A (fr) * 1969-12-18 1971-06-08 Smith Kline French Lab Imidazo et pyrimido -(2,1-b)quinazolines, leurs procedes de preparationet compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
AU5166873A (en) 1974-08-01
DE2305575A1 (de) 1973-08-09
JPS4886894A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-11-15
YU151081A (en) 1983-12-31
FR2173988A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1973-10-12
FR2173988B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-10-22
BE794964A (fr) 1973-08-02
CA1009652A (en) 1977-05-03
DE2305575C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-01-12
JPS5623994B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-06-03
GB1418822A (en) 1975-12-24
AU475978B2 (en) 1976-09-09
HK15581A (en) 1981-05-01

Similar Documents

Publication Publication Date Title
CS183689B2 (en) Process for preparing pyridylphenoxyalkane derivatives
YU42539B (en) Process for obtaining alkanolamine derivatives
YU210773A (en) Process for obtaining imidazoquinazolin-2-one derivatives
YU270780A (en) Process for obtaining dimethyl-2-oxo-3-phenoxypropylphosphonates
YU119773A (en) Process for obtaining morphinane derivatives
YU228873A (en) Process for preparing novel benzoyl-benzofuran derivatives
YU36013B (en) Process for obtaining alfa-aryl-4-substituted piperidinoalkanol derivatives
YU133872A (en) Process for obtaining diphenyl-alkanoylamino-pyridines
YU36527B (en) Process for obtaining 3-hydroxy-cephalosporin
YU296173A (en) Process for obtaining new alkylthiocyclopentanone derivatives
YU81573A (en) Process for obtaining d-homosteroids
HU172069B (hu) Sposob poluchenija proizvodnykh 1-skobka-3-dvojjnozamehhennykh-fosfono-tioureido-skobka zakryta-2-skobka-3-zamehhennykh-ureido- ili -tioureido-skobka zakryta-benzolov
YU299479A (en) Process for obtaining novel aminoimidazoloisoquinoline derivatives
HU171818B (hu) Sposob poluchenija slozhnykh p-difenil-ehfirnykh proizvodnykh omega-arili oksa-prostaglandina
YU36149B (en) Process for obtaining isopropylamines
HU167876B (en) Process for producing 9-10-secoestrane derivatives
HU173381B (hu) Sposob poluchenija proizvodnykh karboksi-ciklopropanov
CH613977A5 (en) Process for preparing tricyclohexyl-tin derivatives
YU35253B (en) Process for preparing 2-imidazolidione derivatives
YU318473A (en) Process for obtaining m-dioxane-5-methylamines
YU146973A (en) Process for obtaining oxo-prostaglandins
YU240180A (en) Process for obtaining deacetoxy-cephalosporin
YU35619B (en) Process for obtaining rifamycine b
YU113673A (en) Process for obtaining novel 1-acyl-homo-pyrimidazole derivatives
YU265473A (en) Process for obtaining 7-acylamido-7-alkoxy-cephalosporins